DEA's marijuana final briefs signal continued opposition posture that gets explicitly extended to psychedelic scheduling commentary within 10 weeks.

The DEA (Drug Enforcement Administration — the US agency that controls which drugs are legal and illegal) has been filing its final arguments in marijuana scheduling hearings, and those arguments show the agency still strongly opposes loosening drug rules. Within the next 10 weeks, that same resistant tone is expected to show up in official comments about rescheduling psilocybin (magic mushrooms) and ibogaine. This matters because the DEA's attitude can slow or block drugs from moving to a less restricted legal category, even when there's medical evidence supporting them.

The final briefs reveal enforcement's institutional stance. That opposition framing carries over directly to any psilocybin/ibogaine scheduling discussion.